Baseline splenic volume as a surrogate marker of FOLFIRINOX efficacy in advanced pancreatic carcinoma.
Fiche publication
Date publication
mai 2018
Journal
Oncotarget
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BORG Christophe, Pr GHIRINGHELLI François, Mme TRUNTZER Caroline, Dr VINCENT Julie, Dr BENGRINE-LEFEVRE Leila
Tous les auteurs :
Aarnink A, Richard C, Truntzer C, Vincent J, Bengrine L, Vienot A, Borg C, Ghiringhelli F
Lien Pubmed
Résumé
The FOLFIRINOX regimen is the standard first-line treatment for advanced pancreatic adenocarcinoma (aPDAC). However, because of its potential toxicity, predictive biomarkers could help clinical decision-making.
Mots clés
FOLFIRINOX, advanced pancreatic carcinoma, biomarker, splenic volume
Référence
Oncotarget. 2018 May 22;9(39):25617-25629